(Source: MARKETWIRE)
Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL) today announced that executive management will participate in the UBS Global Life Sciences Conference to be held September 21 - 23, 2009 at the Grand Hyatt in New York City. Mr. Armando Anido, Chief Executive Officer and President, is scheduled to present an overview of the Company and its product pipeline at 10:30 a.m. EDT on Monday, September 21, 2009.
To listen to the audio web cast of the presentation during or after the event, please visit: http://www.auxilium.com. The replay will be available for ninety days after the event.
About Auxilium
Auxilium Pharmaceuticals, Inc. is a specialty biopharmaceutical company with a focus on developing and marketing to urologists, endocrinologists, orthopedists and select primary care physicians. Auxilium markets Testim(R) 1%, a topical testosterone gel, for the treatment of hypogonadism through its approximately 190-person sales and marketing team. Auxilium has five projects in clinical development. XIAFLEX(TM) (collagenase clostridium histolyticum), formerly referred to as AA4500, has completed phase III clinical trials for the treatment of Dupuytren's disease, and the biologics license application is under review at the FDA for the treatment of Dupuytren's disease. XIAFLEX is in phase IIb of development for the treatment of Peyronie's disease and is in phase II of development for treatment of Frozen Shoulder syndrome (Adhesive Capsulitis). Auxilium's transmucosal film product candidate for the treatment of overactive bladder (AA4010) and its fentanyl pain product using its transmucosal delivery system are in phase I of development. The Company is currently seeking a partner to further develop these product candidates. Auxilium has rights to additional pain products and products for hormone replacement and urologic disease using its transmucosal film delivery system. Auxilium also has options to all indications using XIAFLEX for non-topical formulations. For additional information, visit http://www.auxilium.com.
Safe Harbor Statement
This release contains "forward-looking-statements" within the meaning of The Private Securities Litigation Reform Act of 1995, including statements regarding the Company's intention to present at the UBS Global Life Sciences Conference, and products in development for the treatment of Dupuytren's contracture, Peyronie's disease and Frozen Shoulder Syndrome and for pain, hormone replacement and urologic disease.
